May 22 |
Duos Technologies And 2 Other Stocks Under $3 Insiders Are Buying
|
May 12 |
Ocuphire Pharma First Quarter 2024 Earnings: Misses Expectations
|
May 10 |
Ocuphire Pharma GAAP EPS of -$0.29 misses by $0.20, revenue of $1.71M misses by $2.96M
|
May 10 |
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
|
May 6 |
Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting
|
May 3 |
Ocuphire Pharma to Present at the Aegis Virtual Conference
|
Apr 22 |
Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting
|
Apr 11 |
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
|
Apr 1 |
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
|